Argenica completed FDA-requested safety studies for Xaranetide (ARG-007) and plans a Q3 2026 clinical hold response while advancing a targeted Phase 2b stroke trial.
Written By: Mayuresh Salvi, PharmD
Reviewed By: Pharmacally Editorial Team
Argenica Therapeutics has announced the completion of all safety studies requested by the U.S. Food and Drug Administration to address the clinical hold on its Investigational New Drug application for Xaranetide (ARG-007), an investigational neuroprotective peptide being developed for acute ischaemic stroke. The company reported that the studies identified no new safety concerns and said it expects to submit a comprehensive clinical hold response, including an updated Phase 2b protocol, to the FDA during the third quarter of 2026.
The update, presented during the company’s July 2026 investor presentation, represents an important regulatory milestone as Argenica seeks to initiate a targeted U.S. Phase 2b trial in patients with moderate-to-severe stroke.
FDA-Requested Safety Package Completed
According to Argenica, all three nonclinical safety assays requested by the FDA have now been completed with favourable findings.
The completed studies showed:
- No drug-drug interaction between xaranetide and tenecteplase (TNK), the thrombolytic agent commonly used in acute ischaemic stroke.
- No evidence of genotoxicity in the FDA-requested genotoxicity assay.
- No clinically relevant hERG cardiac safety liability, indicating no apparent risk of QT interval prolongation associated with the investigational therapy.
The company has also completed an acute toxicology study that further characterised the no-observed-adverse-effect level (NOAEL) and maximum tolerated dose (MTD). Together with an updated Investigator’s Brochure and revised Phase 2b clinical protocol, these data will form part of the company’s formal response to the FDA clinical hold.
WHO Assigns International Non-proprietary Name
As part of its regulatory progression, the World Health Organization (WHO) has formally assigned xaranetide as the International Non-proprietary Name (INN) for ARG-007. The designation provides the investigational therapy with its internationally recognised generic name and supports its continued global clinical development.
Post Hoc Phase 2 Analyses Identified Patients Most Likely to Benefit
Alongside the regulatory update, Argenica highlighted post hoc analyses from its completed Phase 2 randomised, placebo-controlled trial evaluating xaranetide in patients with acute ischaemic stroke undergoing endovascular thrombectomy.
Although the primary analysis did not demonstrate a statistically significant treatment benefit across the overall study population, subsequent imaging-based analyses identified clinically meaningful improvements among patients with moderate-to-severe stroke and larger infarct cores.
In this subgroup, xaranetide significantly reduced corrected ischaemic lesion volume compared with placebo (p=0.034) and improved functional recovery measured by the modified Rankin Scale (mRS) at 90 days (p=0.01). Patients with more severe strokes, including those with e-ASPECTS scores of 6 or lower, were significantly more likely to achieve favourable functional outcomes (mRS 0–3) than patients receiving placebo. Additional analyses demonstrated a similar trend in patients with broader imaging criteria, supporting a precision-based treatment approach.
Targeted Phase 2b Trial to Prospectively Confirm Findings
Based on these findings, Argenica is developing a targeted Phase 2b randomised, placebo-controlled trial designed to prospectively evaluate xaranetide in the patient population most likely to benefit from treatment.
The planned study will enrol patients with moderate-to-severe acute ischaemic stroke (ASPECTS 3–8) undergoing mechanical thrombectomy, with AI-assisted imaging used to identify eligible participants. Primary efficacy assessments will include functional recovery measured by the modified Rankin Scale (mRS shift and mRS 0–3), infarct volume reduction, dose-response evaluation, and an interim analysis.
Unlike the exploratory post hoc analyses from the completed Phase 2 study, the upcoming Phase 2b trial will prospectively evaluate these predefined patient selection criteria to determine whether the observed treatment benefits can be confirmed in a larger, targeted population.
Path Forward
Completion of the FDA-requested safety studies represents an important step toward resolving the U.S. clinical hold and advancing xaranetide into late-stage clinical development. If the FDA accepts the company’s response, Argenica intends to initiate its targeted Phase 2b trial in moderate-to-severe acute ischaemic stroke while continuing development of the therapy in additional neurological conditions, including traumatic brain injury.
The company’s revised clinical strategy focuses on prospectively validating the treatment effect observed in patients with more severe stroke, with the goal of establishing xaranetide as a first-in-class neuroprotective therapy capable of reducing secondary brain injury following acute ischaemic stroke.
Reference
Argenica Therapeutics, TECHKNOW INVESTOR PRESENTATION ASX:AGN
About the Writer
Mayuresh Sunil Salvi (Linkedin) is a PharmD professional and healthcare writer with a strong interest in pharmacovigilance, drug safety, and emerging medical research. He is passionate about exploring new drug discoveries, clinical research, and advances in evidence-based medicine. His interests also include ward rounds, prescription audits, and treatment analysis to support rational pharmacotherapy and improved patient care.